Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A

Journal of Hepatology

Volumn 63, Issue 3, 2015, Pages 554-563

  Akamatsu, Sakura ^a   Hayes, C Nelson ^a,b   Ochi, Hidenori ^a,b   Uchida, Takuro ^a   Kan, Hiromi ^a   Murakami, Eisuke ^a   Abe, Hiromi ^a,b   Tsuge, Masataka ^a   Miki, Daiki ^a,b   Akiyama, Rie ^a,b   Hiraga, Nobuhiko ^a,b   Imamura, Michio ^a,b   Aikata, Hiroshi ^a   Kawaoka, Tomokazu ^a,b   Kawakami, Yoshiiku ^a,b   Chayama, Kazuaki ^a,b  

^a HIROSHIMA UNIVERSITY   (Japan)

^b RIKEN   (Japan)

Author keywords

Antiviral resistance; Daclatasvir; Direct acting antivirals; HCV core protein; Interferon lambda 4; ISDR; Next generation sequencing; NS5A; Positive selection; Quasispecies

Indexed keywords

CORE PROTEIN; INTERFERON; INTERFERON LAMBDA 4; NONSTRUCTURAL PROTEIN 5A; UNCLASSIFIED DRUG; VIRUS RNA; IFNL4 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; NS-5 PROTEIN, HEPATITIS C VIRUS; VIRAL PROTEIN;

ADOLESCENT; ADULT; AGED; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; CHILD; CHRONIC HEPATITIS C; CONTROLLED STUDY; ENTROPY; FEMALE; GENE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; INNATE IMMUNITY; INTERFERON LAMBDA 4 GENE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECONDARY STRUCTURE; RETROSPECTIVE STUDY; RNA STRUCTURE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VIRAL CLEARANCE; CHEMISTRY; GENETICS; MIDDLE AGED; PRESCHOOL CHILD; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; FEMALE; GENETIC LOCI; GENOTYPE; HEPATITIS C; HUMANS; INTERLEUKINS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, VIRAL; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84983179336     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.03.033     Document Type: Article

References (53)

1. K. Chayama, F. Mitsui, and C.N. Hayes Optimizing triple therapy and IFN/RBV-free regimens for hepatitis C virus infection Expert Rev Gastroenterol Hepatol 9 2015 21 30
2. C. Lee Discovery of hepatitis C virus NS5A inhibitors as a new class of anti-HCV therapy Arch Pharm Res 34 2011 1403 1407
3. E.M. Quezada, and C.M. Kane The hepatitis C virus NS5A stimulates NS5B during in vitro RNA synthesis in a template specific manner Open Biochem J 3 2009 39 48
4. J.J. Kohler, J.H. Nettles, F. Amblard, S.J. Hurwitz, L. Bassit, R.A. Stanton, and et al. Approaches to hepatitis C treatment and cure using NS5A inhibitors Infect Drug Resist 7 2014 41 56
5. M.J. Gale Jr., M.J. Korth, N.M. Tang, S.L. Tan, D.A. Hopkins, T.E. Dever, and et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein Virology 230 1997 217 227
6. T. Taguchi, M. Nagano-Fujii, M. Akutsu, H. Kadoya, S. Ohgimoto, S. Ishido, and et al. Hepatitis C virus NS5A protein interacts with 2′,5′-oligoadenylate synthetase and inhibits antiviral activity of IFN in an IFN sensitivity-determining region-independent manner J Gen Virol 85 2004 959 969
7. J.W. Schoggins, and C.M. Rice Innate immune responses to hepatitis C virus Curr Top Microbiol Immunol 369 2013 219 242
8. J.M. Pawlotsky NS5A inhibitors in the treatment of hepatitis C J Hepatol 59 2013 375 382
9. C. Sarrazin, and S. Zeuzem Resistance to direct antiviral agents in patients with hepatitis C virus infection Gastroenterology 138 2010 447 462
10. F. Suzuki, Y. Suzuki, N. Akuta, H. Sezaki, H. Yatsuji, Y. Arase, and et al. Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir J Clin Virol 47 2010 76 78
11. S. Nakamoto, T. Kanda, S. Wu, H. Shirasawa, and O. Yokosuka Hepatitis C virus NS5A inhibitors and drug resistance mutations World J Gastroenterol 20 2014 2902 2912
12. H. Kumada, Y. Suzuki, K. Ikeda, J. Toyota, Y. Karino, K. Chayama, and et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection Hepatology 59 2014 2083 2091
13. A.S. Lok, D.F. Gardiner, C. Hezode, E.J. Lawitz, M. Bourliere, G.T. Everson, and et al. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders J Hepatol 60 2014 490 499
14. R.M. Poole Daclatasvir + asunaprevir: first global approval Drugs 74 2014 1559 1571
15. K. Hayashi, Y. Katano, T. Kuzuya, Y. Tachi, T. Honda, M. Ishigami, and et al. Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin J Med Virol 84 2012 438 444
16. Y. Karino, J. Toyota, K. Ikeda, F. Suzuki, K. Chayama, Y. Kawakami, and et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir J Hepatol 58 2013 646 654
17. Y. Suzuki, K. Ikeda, F. Suzuki, J. Toyota, Y. Karino, K. Chayama, and et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options J Hepatol 58 2013 655 662
18. M. Manns, S. Pol, I.M. Jacobson, P. Marcellin, S.C. Gordon, C.Y. Peng, and et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study Lancet 384 2014 1597 1605
19. F. Suzuki, H. Sezaki, N. Akuta, Y. Suzuki, Y. Seko, Y. Kawamura, and et al. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b J Clin Virol 54 2012 352 354
20. M. Miura, S. Maekawa, M. Sato, N. Komatsu, A. Tatsumi, S. Takano, and et al. Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection Hepatol Res 44 2014 E360 E367
21. D.L. Ge, J. Fellay, A.J. Thompson, J.S. Simon, K.V. Shianna, T.J. Urban, and et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401
22. Y. Tanaka, N. Nishida, M. Sugiyama, M. Kurosaki, K. Matsuura, N. Sakamoto, and et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C Nat Genet 41 2009 1105 1109
23. V. Suppiah, M. Moldovan, G. Ahlenstiel, T. Berg, M. Weltman, M.L. Abate, and et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy Nat Genet 41 2009 U1100 U1174
24. H. Sharafi, S.M. Alavian, B. Behnava, A. Pouryasin, and M. Keshvari The impact of IFNL4 rs12979860 polymorphism on spontaneous clearance of hepatitis C. A case-control study Hepat Mon 14 2014 e22649
25. L. Prokunina-Olsson, B. Muchmore, W. Tang, R.M. Pfeiffer, H. Park, H. Dickensheets, and et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus Nat Genet 45 2013 164 171
26. T.R. O'Brien, L. Prokunina-Olsson, and R.P. Donnelly IFN-lambda4: the paradoxical new member of the interferon lambda family J Interferon Cytokine Res 34 2014 829 838
27. V.J. Desmet, M. Gerber, J.H. Hoofnagle, M. Manns, and P.J. Scheuer Classification of chronic hepatitis - Diagnosis, grading and staging Hepatology 19 1994 1513 1520
28. Y. Ohnishi, T. Tanaka, K. Ozaki, R. Yamada, H. Suzuki, and Y. Nakamura A high-throughput SNP typing system for genome-wide association studies J Hum Genet 46 2001 471 477
29. A. Suzuki, R. Yamada, X. Chang, S. Tokuhiro, T. Sawada, M. Suzuki, and et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis Nat Genet 34 2003 395 402
30. N. Akuta, F. Suzuki, Y. Kawamura, H. Yatsuji, H. Sezaki, Y. Suzuki, and et al. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b J Med Virol 79 2007 1686 1695
31. N. Akuta, F. Suzuki, H. Sezaki, Y. Suzuki, T. Hosaka, T. Someya, and et al. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load J Med Virol 78 2006 83 90
32. N. Enomoto, I. Sakuma, Y. Asahina, M. Kurosaki, T. Murakami, C. Yamamoto, and et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis-C virus 1b - Sensitivity to interferon is conferred by amino-acid substitutions in the NS5A region J Clin Invest 96 1995 224 230
33. N. Enomoto, I. Sakuma, Y. Asahina, M. Kurosaki, T. Murakami, C. Yamamoto, and et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection N Engl J Med 334 1996 77 81
34. N. Akuta, F. Suzuki, H. Sezaki, Y. Suzuki, T. Hosaka, M. Kobayashi, and et al. Evolution of simeprevir-resistant variants over time by ultra-deep sequencing in HCV genotype 1b J Med Virol 86 2014 1314 1322
35. P.V. Aka, M.H. Kuniholm, R.M. Pfeiffer, A.S. Wang, W. Tang, S. Chen, and et al. Association of the IFNL4-deltag allele with impaired spontaneous clearance of hepatitis C virus J Infect Dis 209 2014 350 354
36. B.M. Verbist, K. Thys, J. Reumers, Y. Wetzels, K. Van der Borght, W. Talloen, and et al. VirVarSeq: a low-frequency virus variant detection pipeline for Illumina sequencing using adaptive base-calling accuracy filtering Bioinformatics 31 2015 94 101
37. A. Topfer, O. Zagordi, S. Prabhakaran, V. Roth, E. Halperin, and N. Beerenwinkel Probabilistic inference of viral quasispecies subject to recombination J Comput Biol 20 2013 113 123
38. C.N. Hayes, M. Kobayashi, N. Akuta, F. Suzuki, H. Kumada, H. Abe, and et al. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy Gut 60 2011 261 267
39. M. Martinot-Peignoux, P. Marcellin, M. Pouteau, C. Castelnau, N. Boyer, M. Poliquin, and et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C Hepatology 22 1995 1050 1056
40. M.W. Fried, S.J. Hadziyannis, M.L. Shiffman, D. Messinger, and S. Zeuzem Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection J Hepatol 55 2011 69 75
41. K. Tamura, G. Stecher, D. Peterson, A. Filipski, and S. Kumar MEGA6: molecular evolutionary genetics analysis version 6.0 Mol Biol Evol 30 2013 2725 2729
42. I. Kohaar, P. Porter-Gill, P. Lenz, Y.P. Fu, A. Mumy, W. Tang, and et al. Genetic variant as a selection marker for anti-prostate stem cell antigen immunotherapy of bladder cancer J Natl Cancer Inst 105 2013 69 73
43. K. Ye, K.A. Feenstra, J. Heringa, A.P. Ijzerman, and E. Marchiori Multi-RELIEF: a method to recognize specificity determining residues from multiple sequence alignments using a Machine-Learning approach for feature weighting Bioinformatics 24 2008 18 25
44. A.M. Waterhouse, J.B. Procter, D.M. Martin, M. Clamp, and G.J. Barton Jalview Version 2 - A multiple sequence alignment editor and analysis workbench Bioinformatics 25 2009 1189 1191
45. S.L. Pond, S.D. Frost, and S.V. Muse HyPhy: hypothesis testing using phylogenies Bioinformatics 21 2005 676 679
46. S.H. Bernhart, I.L. Hofacker, S. Will, A.R. Gruber, and P.F. Stadler RNAalifold: improved consensus structure prediction for RNA alignments BMC Bioinformatics 9 2008 474
47. A.J. Thompson, A.J. Muir, M.S. Sulkowski, D. Ge, J. Fellay, K.V. Shianna, and et al. IL28B polymorphism improves viral kinetics and is the strongest pre-treatment predictor of SVR in HCV-1 patients Gastroenterology 139 2010 120 129
48. A.U. Neumann, N.P. Lam, H. Dahari, D.R. Gretch, T.E. Wiley, T.J. Layden, and et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy Science 282 1998 103 107
49. T. Sheahan, N. Imanaka, S. Marukian, M. Dorner, P. Liu, A. Ploss, and et al. Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness Cell Host Microbe 15 2014 190 202
50. D.L. Thomas, C.L. Thio, M.P. Martin, Y. Qi, D. Ge, C. O'Huigin, and et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus Nature 461 2009 798 801
51. M. Honda, A. Sakai, T. Yamashita, Y. Nakamoto, E. Mizukoshi, Y. Sakai, and et al. Hepatic ISG expression is associated with genetic variation in IL28B and the outcome of IFN therapy for chronic hepatitis C Gastroenterology 139 2010 499 509
52. M. Sarasin-Filipowicz, E.J. Oakeley, F.H. Duong, V. Christen, L. Terracciano, W. Filipowicz, and et al. Interferon signaling and treatment outcome in chronic hepatitis C Proc Natl Acad Sci U S A 105 2008 7034 7039
53. K. Kosaka, M. Imamura, C.N. Hayes, H. Abe, N. Hiraga, S. Yoshimi, and et al. Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1 J Viral Hepat 22 2015 158 165